Positive News SentimentPositive NewsNASDAQ:CTMX CytomX Therapeutics (CTMX) Stock Price, News & Analysis $2.08 +0.02 (+0.72%) As of 02:46 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock About CytomX Therapeutics Stock (NASDAQ:CTMX) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get CytomX Therapeutics alerts:Sign Up Key Stats Today's Range$2.09▼$2.1850-Day Range$1.76▼$2.6052-Week Range$0.40▼$3.10Volume740,576 shsAverage Volume3.27 million shsMarket Capitalization$343.84 millionP/E Ratio3.72Dividend YieldN/APrice Target$5.75Consensus RatingBuy Company Overview CytomX Therapeutics, Inc., an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology. It also develops CX-904, a T-cell-engaging bispecific antibody targeting the epidermal growth factor receptor (EGFR) on tumor cells and the CD3 receptor on T cells; CX-2051, a conditionally activated ADC for optimizing the therapeutic index for EpCAM-expressing epithelial cancers, including colorectal cancer; and CX-801, an interferon alpha-2b PROBODY cytokine. In addition, the company's development pipeline comprises CX-2029, a conditional activated ADC targeting CD71; and BMS-986288, a PROBODY version of non-fucosylated ipilimumab. It has strategic collaborations with Amgen, Astellas, Bristol Myers Squibb, Regeneron, and Moderna. CytomX Therapeutics, Inc. was founded in 2008 and is headquartered in South San Francisco, California. Read More CytomX Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks87th Percentile Overall ScoreCTMX MarketRank™: CytomX Therapeutics scored higher than 87% of companies evaluated by MarketBeat, and ranked 143rd out of 949 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingCytomX Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageCytomX Therapeutics has only been the subject of 1 research reports in the past 90 days.Read more about CytomX Therapeutics' stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for CytomX Therapeutics are expected to decrease in the coming year, from ($0.05) to ($0.33) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of CytomX Therapeutics is 3.74, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 28.67.Price to Earnings Ratio vs. SectorThe P/E ratio of CytomX Therapeutics is 3.74, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 30.76.Price to Book Value per Share RatioCytomX Therapeutics has a P/B Ratio of 2.87. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about CytomX Therapeutics' valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted31.82% of the float of CytomX Therapeutics has been sold short.Short Interest Ratio / Days to CoverCytomX Therapeutics has a short interest ratio ("days to cover") of 4.9.Change versus previous monthShort interest in CytomX Therapeutics has recently increased by 0.38%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldCytomX Therapeutics does not currently pay a dividend.Dividend GrowthCytomX Therapeutics does not have a long track record of dividend growth. Sustainability and ESG4.7 / 5Environmental Score-0.74 Percentage of Shares Shorted31.82% of the float of CytomX Therapeutics has been sold short.Short Interest Ratio / Days to CoverCytomX Therapeutics has a short interest ratio ("days to cover") of 4.9.Change versus previous monthShort interest in CytomX Therapeutics has recently increased by 0.38%, indicating that investor sentiment is decreasing. News and Social Media3.8 / 5News Sentiment1.88 News SentimentCytomX Therapeutics has a news sentiment score of 1.88. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.99 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for CytomX Therapeutics this week, compared to 2 articles on an average week.Search Interest6 people have searched for CTMX on MarketBeat in the last 30 days. This is an increase of 500% compared to the previous 30 days.MarketBeat Follows2 people have added CytomX Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, CytomX Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 6.60% of the stock of CytomX Therapeutics is held by insiders.Percentage Held by Institutions67.77% of the stock of CytomX Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about CytomX Therapeutics' insider trading history. Receive CTMX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for CytomX Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. CTMX Stock News HeadlinesCytomX Therapeutics to Present at Upcoming September Investor ConferencesAugust 28 at 8:00 AM | globenewswire.comCytomX Therapeutics Updates on CX-2051 Phase 1 StudyAugust 15, 2025 | msn.comMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tariffs just lit the fuse. Millions of investors are blindsided as stocks plunge… but this is only Phase 1. If you're still holding the wrong assets, you could lose 30% or more in the coming weeks.August 28 at 2:00 AM | American Alternative (Ad)CytomX trial ongoing despite grade five event, says OppenheimerAugust 13, 2025 | msn.comCytomX Therapeutics Provides Update on CX-2051 Phase 1 StudyAugust 13, 2025 | globenewswire.comCytomX Therapeutics Earnings Call: Clinical Progress and Financial StrengthAugust 13, 2025 | msn.comCytomX Therapeutics, Inc. (NASDAQ:CTMX) Q2 2025 Earnings Call TranscriptAugust 13, 2025 | msn.comCytomX Therapeutics, Inc. (CTMX) Q2 2025 Earnings Call TranscriptAugust 8, 2025 | seekingalpha.comSee More Headlines CTMX Stock Analysis - Frequently Asked Questions How have CTMX shares performed this year? CytomX Therapeutics' stock was trading at $1.03 at the beginning of 2025. Since then, CTMX shares have increased by 103.4% and is now trading at $2.0950. How were CytomX Therapeutics' earnings last quarter? CytomX Therapeutics, Inc. (NASDAQ:CTMX) announced its earnings results on Monday, May, 12th. The biotechnology company reported $0.27 earnings per share for the quarter, topping analysts' consensus estimates of $0.18 by $0.09. The biotechnology company had revenue of $50.92 million for the quarter, compared to the consensus estimate of $35.42 million. CytomX Therapeutics had a net margin of 34.04% and a trailing twelve-month return on equity of 158.70%. Read the conference call transcript. Who are CytomX Therapeutics' major shareholders? CytomX Therapeutics' top institutional shareholders include Orbimed Advisors LLC (10.50%), Commodore Capital LP (9.54%), Perceptive Advisors LLC (8.67%) and Franklin Resources Inc. (7.16%). Insiders that own company stock include Sean A Mccarthy, Marcia Belvin, Christopher Ogden, Lloyd A Rowland, Jeffrey B Landau, Carlos Campoy and Elaine V Jones. View institutional ownership trends. How do I buy shares of CytomX Therapeutics? Shares of CTMX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of CytomX Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that CytomX Therapeutics investors own include NVIDIA (NVDA), Broadcom (AVGO), Arista Networks (ANET), Meta Platforms (META), CymaBay Therapeutics (CBAY), Adobe (ADBE) and CrowdStrike (CRWD). Company Calendar Last Earnings5/12/2025Today8/28/2025Next Earnings (Estimated)11/06/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:CTMX CIK1501989 Webwww.cytomx.com Phone(605) 515-3185Fax650-351-0353Employees170Year Founded2008Price Target and Rating Average Price Target for CytomX Therapeutics$5.75 High Price Target$7.00 Low Price Target$5.00 Potential Upside/Downside+177.8%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage4 Analysts Profitability EPS (Trailing Twelve Months)$0.56 Trailing P/E Ratio3.70 Forward P/E RatioN/A P/E GrowthN/ANet Income$31.87 million Net Margins34.04% Pretax Margin34.18% Return on Equity158.70% Return on Assets36.04% Debt Debt-to-Equity RatioN/A Current Ratio4.20 Quick Ratio4.20 Sales & Book Value Annual Sales$138.10 million Price / Sales2.47 Cash Flow$0.37 per share Price / Cash Flow5.61 Book Value$0.73 per share Price / Book2.84Miscellaneous Outstanding Shares164,910,000Free Float154,029,000Market Cap$341.36 million OptionableOptionable Beta2.13 Social Links A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for September 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.Get This Free Report This page (NASDAQ:CTMX) was last updated on 8/28/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredWhat Steve Bannon revealed about Trump’s gold playA Trump advisor just said 3 words that could reset the dollar. It’s a gold move nobody saw coming—and your ...Reagan Gold Group | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredAltucher: It Looks Like My Trump prediction is coming trueNew Hampshire just launched a Strategic Crypto Reserve — and James Altucher says it’s the first sign that “Tru...Paradigm Press | Sponsored“Sell Nvidia before earnings”Eric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has bee...InvestorPlace | SponsoredTake a look at this picture ...A strange investment secret — discovered just a few short weeks before this image was taken — correctly predic...Weiss Ratings | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CytomX Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share CytomX Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.